medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2022, Número 2

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2022; 20 (2)


Principales fármacos usados en tricología

Morales MAY, Barrón HYL, Dávila y Aranda ZME, Macías SHS, Karam OM

Idioma: Español
Referencias bibliográficas: 112
Paginas: 231-244
Archivo PDF: 186.96 Kb.


RESUMEN

Durante los últimos años se ha incrementado exponencialmente el interés de la comunidad médica y dermatológica por la tricología, así como la búsqueda de atención médica por parte de los pacientes que padecen alopecia. Por esta razón, surge la necesidad de conocer a profundidad los mecanismos de acción, principios farmacológicos, efectos secundarios y contraindicaciones de los medicamentos y sustancias activas usados en la práctica tricológica.
El objetivo de este artículo es hacer una revisión general de las características farmacológicas de los medicamentos que se utilizan actualmente con mayor frecuencia tanto en alopecias cicatriciales como no cicatriciales, los cuales incluyen: inhibidores de 5-alfa reductasa como finasterida y dutasterida, metotrexato, isotretinoína, minoxidil e hidroxicloroquina.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP et al.,Efficacy and safety of finasteride therapy for benign prostatic hyperplasia:results of a 2-year randomized controlled trial, cmaj 1996;155(9):1251-9.

  2. Godoy A, Kawinski E, Li Y, Oka D, Alexiev B, Azzouni F et al.,5α-reductase type 3 expression in human benign and malignant tissues:a comparative analysis during prostate cancer progression, Prostate2011; 71:1033-46.

  3. Azzouni F, Godoy A, Li Y y Mohler J, The 5-alpha reductase isozymefamily: a review 787 of basic biology and their role in human diseases,Adv Urol 2012; 2012:530121.788.

  4. Fernández J y Armario J, Estado actual del uso de finasterida en eltratamiento de la alopecia androgenética, Piel 2001; 16:265-8.

  5. Dallob AL, Sadick NS, Unger W, Lipert S, Geissler LA et al., The effectof finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosteroneand dihydrotestosterone concentrations in patients with male patternbaldness, J Clin Endocrinol Metab 1994; 79(3):703-6.

  6. Lee SW, Juhasz M, Mobasher P, Ekelem C y Mesinkovska NA, A systematicreview of topical finasteride in the treatment of androgeneticalopecia in men and women, J Drugs Dermatol 2018; 17(4):457-63.

  7. Leyden J, Dunlap F, Miller B, Winters P, Lebwohl M et al., Finasteride inthe treatment of men with frontal male pattern hair loss, J Am AcadDermatol 1999; 40(6 Pt 1):930-7.

  8. Kelly Y, Blanco A y Tosti A, Androgenetic alopecia: an update of treatmentoptions, Drugs 2016; 76(14):1349-64.

  9. Van Zuuren EJ, Fedorowicz Z y Schoones J, Interventions for femalepattern hair loss, Cochrane Database Syst Rev 2016; 5(5):cd007628.

  10. Kanti V, Messenger A, Dobos G, Reygangne P, Finner A et al., Evidence-based (s3) guideline for the treatment of androgenetic alopeciain women and in men, short versión, J Eur Dermatol Venereol 2018;32(1):11-22.

  11. Iorizzo M, Vincenzi C, Voudouris S, Piraccini BM y Tosti A, Finasteridetreatment of female pattern hair loss. Arch Dermatol 2006; 142(3):298-302.

  12. Whiting DA, Waldstreicher J, Sánchez M y Kaufman KD, Measuringreversal of hair miniaturization in androgenetic alopecia by folicularcounts in horizontal sections of serial scalp biopsies: results of finasteride1 mg treatment of men and postmenopausal women, J InvestigDermatol Sym Proc 1999; 4(3):282-4.

  13. Kim WJ, Song M, Ko HC, Kim BS y Kim MB, Efficacy of finasteride1.25mg on female pattern hair loss; pilot study, Ann Dermatol 2012;24(3):370-2.

  14. Carmina E y Lobo RA, Treatment of hyperandrogenic alopecia inwomen, Fertil Steril 2003; 79(1):91-5.

  15. Mardones F y Shapiro J, Lichen planopilaris in a Latin American (Chilean)population: demographics, clinical profile and treatment experience,Clin Exp Dermatol 2017; 42(7):755-9.

  16. Arshdeep, Kubba R, Bergfeld WF y Srinivas CR, Finasteride in frontalfibrosing alopecia: joining the dots!, Skin Appendage Disord 2020;6(3):182-3.

  17. Gamret AC, Potluri VS, Krishnamurthy K y Fertig RM, Frontal fibrosingalopecia: efficacy of treatment modalities, Int J Womens Health 2019;11:273-85.

  18. Vañó-Galván S, Molina-Ruiz AM, Serrano-Falcón C, Arias-Santiago S,Rodrigues-Barata AR et al., Frontal fibrosing alopecia: a multicenterreview of 355 patients, J Am Acad Dermatol 2014; 70(4):670-8.

  19. Fertig R y Tosti A, Frontal fibrosing alopecia treatment options, IntractableRare Dis Res 2016; 5(4):314-5.

  20. Imhof RL, Chaudhry HM, Larkin SC, Torgerson RR y Tolkachjov SN,Frontal fibrosing alopecia in women: the Mayo Clinic experience with148 patients, 1992-2016, Mayo Clin Proc 2018; 93(11):1581-8.

  21. GlaxoSmithKline UK, Avodart of new treatment for benign prostatichiperplasia. Disponible en: http://emc.vhn.net.

  22. Oleszewka M y Rudnicka L, Effective treatment of female androgenicalopecia with dutasteride, J Drugs Dermatol 2005; 4:637-40.

  23. Shanshanwal SJ y Dhurat RS, Superiority of dutasteride over finasteridein hair regrowth and reversal of miniaturization in men with androgeneticalopecia: a randomized controlled open-label, evaluatorblindedstudy, Indian J Dermatol Venereol Leprol 2017; 83:47-54.

  24. Premanand A y Reena Rajkumari B, Androgen modulation of wnt/β-catenin signaling in androgenetic alopecia, Arch Dermatol Res 2018;310(5):391-9.

  25. Shanshanwal SJ y Dhurat RS, Superiority of dutasteride over finasteridein hair regrowth and reversal of miniaturization in men with androgeneticalopecia: a randomized controlled open-label, evaluatorblindedstudy, Indian J Dermatol Venereol Leprol 2017; 83:47-54.

  26. Vañó-Galván S, Saceda-Corralo D, Moreno-Arrones OM, Rodrigues-Barata R, Morales C et al., Effectiveness and safety of oral dutasteridefor male androgenetic alopecia in real clinical practice: a descriptivemonocentric study, Dermatol Ther 2020; 33(1):18-21.

  27. Corralo D, Rodrigues-Barata R, Vañó-Galván S y Jaén-Olasolo P, Mesotherapywith dutasteride in the treatment of androgenetic alopecia,Int J Trichology 2018; 9(1):50-3.

  28. Brough K y Rochelle R, Hormonal therapy in female pattern hair loss,Int J of Womens’s Dermatology 2017; 3(1):53-7.

  29. Boresman I, Orgie A y Grimalt R, The effectiveness of finasteride anddutasteride use for 3 years in women with androgenetic alopecia, JDermatol Venerol Leporl 2014; 80:521-5.

  30. Oleszewka M y Rudnicka L, Effective treatment of female androgenicalopecia with dutasteride, J Drugs Dermatol 2005; 4:637-40.

  31. Katoulis A, Georgala, Bozi E, Papadavid E, Kalogeromitros D y StavrianeasN, Frontal fibrosing alopecia: treatment with oral dutasterideand topical pimecrolimus, J Eur Acad Dermatol Venereol 2009; 23(5):580-2.

  32. Ladizinski B, Bazakas A, Selim MA y Olsen EA, Frontal fibrosing alopecia:a retrospective review of 19 patients seen at Duke University. J AmAcad Dermatol 2013; 68(5):749-55.

  33. Georgala S, Katoulis AC, Befon A, Danopoulou I y Georgala C, Treatmentof postmenopausal frontal fibrosing alopecia with oral dutasteride,J Am Acad Dermatol 2009; 61(1):157-8.

  34. Pindado-Ortega C, Saceda-Corralo D, Moreno-Arrones OM, Rodrigues-Barata AR, Hermosa-Gelbard et al., Effectiveness of dutasteridein a large series of patients with frontal fibrosing alopecia in realclinical practice, J Am Acad Dermatol 2021; 84(5):1285-94.

  35. Iorizzo M y Tosti A, Frontal fibrosing alopecia: an update on pathogenesis,diagnosis, and treatment, Am J Clin Dermatol 2019; 20(3):379-90.

  36. Ho A y Shapiro J, Medical therapy for frontal fibrosing alopecia: areview and clinical approach, J Am Acad Dermatol 2019; 81(2):568-80.

  37. Lee S, Lee YB, Choe SJ y Lee WS, Adverse sexual effects of treatmentwith finasteride or dutasteride for male androgenetic alopecia:a systematic review and metaanalysis, Acta Derm Venerol 2019; 99:12-7.

  38. Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC y Reichenberg J,Adverse effects and safety of 5-alpha reductase inhibitors: a systematicreview, J Clin Aesthet Dermatol 2016; 9(7):56-62.

  39. Mondiani N, Gontero P, Giubielei G, Giuseppe L, Cai Tommasoet al., Finasteride 5 mg and sexual side effects: how many of these arerelated to a nocebo phenomenon?, J Sex Med 2007; 4:1708-12.

  40. Traish AM, Health risks associated with long-term finasteride anddutasteride use: its time to sound the alarm, World J Mens Health 2020;38(3):323-37.

  41. Pereira AF y De Coelho TO, Post-finasteride syndrome, An Bras Dermatol2020; 95(3):271-7.

  42. Fertig R, Shapiro J, Bergfeld W y Tosti A, Investigation of the plausibilityof 5-alpha-reductase inhibitor syndrome, Skin Appendage Disord2016; 2(3-4):120-9.

  43. Puig L, Metotrexato: novedades terapéuticas, Actas Dermo-Sifiliográficas2014; 105(6):83-9.

  44. Serrano P y Mascaró J, Metotrexato: actualización en el tratamientode la psoriasis, Piel, Formación Continuada en Dermatología 2006;21(7):358-63.

  45. Carretero G, Puig L, Dehesa L, Carrascosa J, Ribera M et al., Metotrexato:guía de uso en psoriasis, Actas Dermosifiliográficas 2010; 101(7):600-13.

  46. Joly P, The use of methotrexate alone or in combination with lowdoses of oral corticosteroids in the treatment of alopecia totalis oruniversalis, J Am Acad Dermatol 2006; 55(4):632-6.

  47. Phan K, Ramachandran V y Sebaratnam DF, Methotrexate for alopeciaareata: a systematic review and meta-analysis, J Am Acad Dermatol2019; 80(1):120-7.

  48. Lai VW, Chen G, Gin D y Sinclair R, Systemic treatments for alopeciaareata: a systematic review, Australas J Dermatol 2019; 60(1):e1-13.

  49. Fukumoto T, Fukumoto R, Magno E, Oka M, Nishigori C y HoritaN, Treatments for alopecia areata: a systematic review and networkmeta-analysis, Dermatol Ther 2021; 34(3):e14916.

  50. Imhof RL, Chaudhry HM, Larkin SC, Torgerson RR y Tolkachjov SN,Frontal fibrosing alopecia in women: the Mayo Clinic experience with148 patients, 1992-2016, Mayo Clin Proc 2018; 93(11):1581-8.

  51. Morandi Stumpf MA, Do Valenga Baroni ER y Schafranski MD, Frontalfibrosing alopecia: successfully treated with methotrexate or justthe natural disease progression?, Acta Dermatovenerol Croat 2020;28(3):188-9.

  52. Svigos K, Yin L, Fried L, Lo Sicco K y Shapiro J, A practical approach tothe diagnosis and management of classic lichen planopilaris, Am J ClinDermatol 2021; 22(5):681-92.

  53. Bulbul Baskan E y Yazici S, Treatment of lichen planopilaris: methotrexateor cyclosporine a therapy?, Cutan Ocul Toxicol 2018; 37(2):196-9.

  54. Babahosseini H, Tavakolpour S, Mahmoudi H, Balighi K, TeimourpourA et al., Lichen planopilaris: retrospective study on the characteristicsand treatment of 291 patients, J Dermatolog Treat 2019; 30(6):598-604.

  55. Khalil NY, Darwish IA y Al-Qahtani AA, Isotretinoin, Profiles Drug SubstExcip Relat Methodol 2020; 45:119-57.

  56. Melnik BC, Apoptosis may explain the pharmacological mode of actionand adverse effects of isotretinoin, including teratogenicity, ActaDerm Venereol 2017; 97(2):173-81.

  57. Forbat E, Ali FR y Al-Niaimi F, Dermatological indications for the useof isotretinoin beyond acne, J Dermatolog Treat 2018; 29(7):698-705.

  58. Rademaker M, Low-dose isotretinoin for seborrhoeic dermatitis, J CutanMed Surg 2017; 21(2):170-1.

  59. Orfanos CE, Zouboulis CC, Almond-Roesler B y Geilen CC, Currentuse and future potential role of retinoids in dermatology, Drugs 1997;53(3):358-88.

  60. Abbas O, Chedraoui A y Ghosn S, Frontal fibrosing alopecia presentingwith components of Piccardi-Lassueur-Graham-Little syndrome, JAm Acad Dermatol 2007; 57(2 Suppl):S15-8.

  61. Donati A, Molina L, Doche I, Valente NS y Romiti R, Facial papules infrontal fibrosing alopecia: evidence of vellus follicle involvement, ArchDermatol 2011; 147(12):1424-7.

  62. Pedrosa AF, Duarte AF, Haneke E y Correia O, Yellow facial papulesassociated with frontal fibrosing alopecia: a distinct histologic patternand response to isotretinoin, J Am Acad Dermatol 2017; 77(4):764-6.

  63. Pirmez R, Barreto T, Duque-Estrada B, Quintella DC y Cuzzi T, Facialpapules in frontal fibrosing alopecia: beyond vellus hair follicle involvement,Skin Appendage Disord 2018; 4(3):145-9.

  64. Pedrosa AF, Duarte AF, Haneke E y Correia O, Reply to: “Histopathologyof facial papules in frontal fibrosing alopecia and therapeuticresponse to oral isotretinoin”, J Am Acad Dermatol 2018;78(2):e47-8.

  65. Batra P, Sukhdeo K y Shapiro J, Hair loss in lichen planopilaris andfrontal fibrosing alopecia: not always irreversible, Skin Appendage Disord2020; 6(2):125-9.

  66. Rakowska A, Gradzin´ska A, Olszewska M y Rudnicka L, Efficacy ofisotretinoin and acitretin in treatment of frontal fibrosing alopecia:retrospective analysis of 54 cases, J Drugs Dermatol 2017; 16(10):988-92.

  67. Mahmoudi H, Rostami A, Tavakolpour S, Nili A, Teimourpour A et al.,Oral isotretinoin combined with topical clobetasol 0.05% and tacrolimus0.1% for the treatment of frontal fibrosing alopecia: a randomizedcontrolled trial, J Dermatolog Treat 2020; 20:1-7.

  68. Chiarini C, Torchia D, Bianchi B, Volpi W, Caproni M et al., Immunopathogenesisof folliculitis decalvans: clues in early lesions, Am J ClinPathol 2008; 130(4):526-34.

  69. Zouboulis CC, Isotretinoin revisited: pluripotent effects on human sebaceousgland cells, J Invest Dermatol 2006; 126(10):2154-6.

  70. Dispenza MC, Wolpert EB, Gilliland KL, Dai JP, Cong Z, Nelson AM yThiboutot DM, Systemic isotretinoin therapy normalizes exaggeratedtlr-2-mediated innate immune responses in acne patients, J InvestDermatol 2012; 132(9):2198-205.

  71. Tietze JK, Heppt MV, Von Preußen A, Wolf U, Ruzicka T, Wolff Hy Sattler EC, Oral isotretinoin as the most effective treatment in folliculitisdecalvans: a retrospective comparison of different treatmentregimens in 28 patients, J Eur Acad Dermatol Venereol 2015; 29(9):1816-21.

  72. Aksoy B, Hapa A y Mutlu E, Isotretinoin treatment for folliculitis decalvans:a retrospective case-series study, Int J Dermatol 2018; 57(2):250-3.

  73. Georgala S, Korfitis C, Ioannidou D, Alestas T, Kylafis G y Georgala C,Dissecting cellulitis of the scalp treated with rifampicin and isotretinoin:case reports, Cutis 2008; 82(3):195-8.

  74. Chu S, Michelle L, Ekelem C, Sung CT, Rojek N et al., Oral isotretinoinfor the treatment of dermatologic conditions other than acne: a systematicreview and discussion of future directions, Arch Dermatol Res2021; 313(6):391-430.

  75. Guo W, Zhu C, Stevens G y Silverstein D, Analyzing the efficacy ofisotretinoin in treating dissecting cellulitis: a literature review and meta-analysis, Drugs rd 2021; 21(1):29-37.

  76. Zeglaoui F, Zoghlami A, Fazaa B y Kamoun MR, Dissecting cellulitis ofthe scalp: response to isotretinoin, J Eur Acad Dermatol Venereol 2007;21(10):1430-1.

  77. Ellis CN y Krach KJ, Uses and complications of isotretinoin therapy, JAm Acad Dermatol 2001; 45(5):S150-7.

  78. National Center for Biotechnology Information, PubChem CompoundSummary for cid 3652, Hydroxychloroquine. Disponible en:https://pubchem.ncbi.nlm.nih.gov/compound/Hydroxychloroquine.Accessed Jan. 29, 2022.

  79. Ochsendorf FR, Use of antimalarials in dermatology, J Dtsch DermatolGes 2010; 8(10):829-44; Quiz 845.

  80. Torres-Guerrero E y Durán-Navarro LL, Principales fármacos utilizadosen dermatología. En Guzmán R, Dermatología. Atlas, diagnóstico ytratamiento, 7ª ed., México, McGraw Hill; 2019.

  81. Sardana K, Sinha S y Sachdeva S, Hydroxychloroquine in dermatologyand beyond: recent update, Indian Dermatol Online J 2020; 11(3):453-64.

  82. Chew CY, Mar A, Nikpour M y Saracino AM, Hydroxychloroquine indermatology: new perspectives on an old drug, Australas J Dermatol2020; 61(2):e150-7.

  83. Schrezenmeier E y Dorner T, Mechanisms of action of hydroxychloroquineand chloroquine: implications for rheumatology, Nat RevRheumatol 2020; 16(3):155-66.

  84. Rodriguez-Caruncho C y Bielsa Marsol I, Antimalarials in dermatology:mechanism of action, indications, and side effects, Actas Dermosifiliogr2014; 105(3):243-52.

  85. Gamret AC, Potluri VS, Krishnamurthy K y Fertig RM, Frontal fibrosingalopecia: efficacy of treatment modalities, Int J Womens Health2019; 11:273-85.

  86. Maldonado Cid P, Leis Dosil VM, Garrido Gutiérrez C et al., Frontalfibrosing alopecia: a retrospective study of 75 patients, Actas Dermosifiliogr(Inglaterra) 2020; 111(6):487-95.

  87. Filotico R y Mastrandrea V, Cutaneous lupus erythematosus: clinicopathologiccorrelation, G Ital Dermatol Venereol 2018; 153(2):216-29.

  88. Jessop S, Whitelaw DA, Grainge MJ y Jayasekera P, Drugs for discoidlupus erythematosus, Cochrane Database Syst Rev 2017; 5:cd002954.

  89. Naeini FF, Saber M, Asilian A y Hosseini SM, Clinical efficacy andsafety of methotrexate versus hydroxychloroquine in preventing lichenplanopilaris progress: a randomized clinical trial, Int J Prev Med2017; 8:37.

  90. Nic Dhonncha E, Foley CC y Markham T, The role of hydroxychloroquinein the treatment of lichen planopilaris: a retrospective caseseries and review, Dermatol Ther 2017; 30(3).

  91. Barton VR, Toussi A, Awasthi S y Kiuru M, Treatment of pediatricalopecia areata: a systematic review, J Am Acad Dermatol 2021; S0190-9622(21)00922-1.077. Publicado en línea.

  92. Waskiel-Burnat A, Kotodziejak M, Sikora M et al., Therapeutic managementin paediatric alopecia areata: a systematic review, J Eur AcadDermatol Venereol 2021; 35(6):1299-308.

  93. Gupta AK, Talukder M, Venkataraman M y Bamimore MA, Minoxidil:a comprehensive review, J Dermatolog Treat 2021; 1-11. Publicado enlínea.

  94. Suchonwanit P, Thammarucha S y Leerunyakul K, Minoxidil andits use in hair disorders: a review, Drug Des Devel Ther 2019; 13:2777-86.

  95. Meisheri KD, Cipkus LA y Taylor CJ, Mechanism of action of minoxidilsulfate-induced vasodilation: a role for increased K+ permeability,J Pharmacol Exp Ther 1988; 245(3):751-60.

  96. Randolph M y Tosti A, Oral minoxidil treatment for hair loss: a reviewof efficacy and safety, J Am Acad Dermatol 2021; 84(3):737-46.

  97. Mori O y Uno H, The effect of topical minoxidil on hair follicularcycles of rats, J Dermatol 1990; 17(5):276-81.

  98. Lachgar S, Charveron M, Gall Y y Bonafe JL, Minoxidil upregulatesthe expression of vascular endothelial growth factor in human hairdermal papilla cells, Br J Dermatol 1998; 138(3):407-11.

  99. Michelet JF, Commo S, Billoni N, Mahé YF y Bernard BA, Activationof cytoprotective prostaglandin synthase-1 by minoxidil as a possibleexplanation for its hair growth-stimulating effect, J Invest Dermatol1997; 108(2):205-9.

  100. Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM et al.,A randomized clinical trial of 5% topical minoxidil versus 2% topicalminoxidil and placebo in the treatment of androgenetic alopecia inmen, J Am Acad Dermatol 2002; 47(3):377-85.

  101. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F et al., A randomized,placebo-controlled trial of 5% and 2% topical minoxidil solutions inthe treatment of female pattern hair loss, J Am Acad Dermatol 2004;50(4):541-53.

  102. Tsuboi R, Tanaka T, Nishikawa T, Ueki R, Yamada H et al., A randomized,placebo-controlled trial of 1% topical minoxidil solution inthe treatment of androgenetic alopecia in Japanese women, Eur JDermatol 2007; 17(1):37-44.

  103. Blume-Peytavi U, Hillmann K, Dietz E, Canfield D y García BartelsN, A randomized, single-blind trial of 5% minoxidil foam oncedaily versus 2% minoxidil solution twice daily in the treatment ofandrogenetic alopecia in women, J Am Acad Dermatol 2011; 65(6):1126-34.e2.

  104. Olsen EA, Whiting D, Bergfeld W, Jeffrey M, Hordinski M et al., Amulticenter, randomized, placebo-controlled, double-blind clinicaltrial of a novel formulation of 5% minoxidil topical foam versus placeboin the treatment of androgenetic alopecia in men, J Am AcadDermatol 2007; 57(5):767-74.

  105. Dias PCR, Miot HA, Trüeb RM y Ramos PM, Use of minoxidil sulfateversus minoxidil base in androgenetic alopecia treatment: friend orfoe?, Skin Appendage Disord 2018; 4(4):349-50.

  106. Rodrigues-Barata R, Moreno-Arrones OM, Saceda-Corralo D, Jiménez-Cauhé J, Ortega-Quijano D et al., Low-dose oral minoxidil forfemale pattern hair loss: a unicenter descriptive study of 148 women,Skin Appendage Disord 2020; 6(3):175-6.

  107. Sinclair RD, Female pattern hair loss: a pilot study investigating combinationtherapy with low-dose oral minoxidil and spironolactone, IntJ Dermatol 2018; 57(1):104-9.

  108. Fiedler-Weiss VC, Rumsfield J, Buys CM, West DP y Wendrow A,Evaluation of oral minoxidil in the treatment of alopecia areata, ArchDermatol 1987; 123(11):1488-90.

  109. Wambier CG, Craiglow BG y King BA, Tratamento adjuvante comminoxidil oral para tratamento de alopecia areata refratária a inibidoresde jak, Surgical & Cosmetic Dermatology 2020; 12(1):74-5.

  110. Perera E y Sinclair R, Treatment of chronic telogen effluvium withoral minoxidil: a retrospective study, 2017; 6:1650. F1000Res. Publicadoen línea.

  111. Tosti A, Piraccini BM, Iorizzo M y Misciali C, Frontal fibrosing alopeciain postmenopausal women, J Am Acad Dermatol 2005; 52(1):55-60.

  112. Cranwell WC y Sinclair R, Familial frontal fibrosing alopecia treatedwith dutasteride, minoxidil and artificial hair transplantation, AustralasJ Dermatol 2017; 58(3):e94-6.




2020     |     www.medigraphic.com